{"id":395867,"date":"2019-05-16T00:00:00","date_gmt":"2019-05-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0009-2019-biopharma-chronic-pain-special-topics-us-2019\/"},"modified":"2026-04-15T09:54:42","modified_gmt":"2026-04-15T09:54:42","slug":"sptocg0009-2019-biopharma-chronic-pain-special-topics-us-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/sptocg0009-2019-biopharma-chronic-pain-special-topics-us-2019\/","title":{"rendered":"Chronic Pain | Special Topics | US | 2019"},"content":{"rendered":"<p>The most highly anticipated analgesic drugs in late-phase development belong to the anti-nerve growth factor (NGF) class: Pfizer \/ Eli Lilly\u2019s tanezumab and Regeneron \/ Teva \/ Mitsubishi Tanabe\u2019s fasinumab. As the first injectable biologics expected to launch in the crowded and highly generic oral chronic pain market, these drugs have the potential to disrupt the current later-line treatment algorithm of chronic pain patients. Despite demonstrations of impressive efficacy results in clinical trials, lingering concerns about the safety of this class may constrain prescribing. However, the need for less-addictive yet potent analgesics for chronic pain patients may lead physicians to overcome such concerns to provide robust analgesia to chronic pain patients without chronic use of opioid analgesics. We explore attitudes toward anti-NGF drugs and the potential disruption of treatment paradigms with the anticipated launch of these drugs.<\/p>\n<p><strong>QUESTIONS ANSWERED:<\/strong><\/p>\n<ul>\n<li>How do physicians plan to prescribe the anti-NGF drugs? What prescription therapies or surgical treatments will be impacted by the availability of the anti-NGF drugs?<\/li>\n<li>How have clinical trial data affected physicians\u2019 attitudes toward the anti-NGF drugs\u2019 safety profiles in chronic pain patients? What are the top reasons some physicians would refrain from prescribing the anti-NGF drugs?<\/li>\n<li>To what extent do physicians differentiate between tanezumab and fasinumab, and what factors influence their preferences?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States<\/p>\n<p><strong>Primary Research:<\/strong> Survey of 52 U.S. pain specialists and 50 U.S. rheumatologists<\/p>\n<p><strong>Key Drugs Covered:<\/strong> Tanezumab, fasinumab<\/p>\n<p><strong>Content Highlights:<\/strong> Physician willingness to prescribe anti-NGF drugs. Factors influencing use of anti-NGF drugs. Anticipated use of anti-NGF drugs and their expected impact on medical practice. Key obstacles to uptake of anti-NGF drugs.<\/p>\n<p><strong>PRODUCT DESCRIPTION:<\/strong> Special Topics uses quantitative primary research to assess evolving trends and market effects in dynamic disease areas. The report examines topics of high interest to an indication, such as delving into reasons driving physicians\u2019 prescribing decisions or assessing physicians\u2019 receptivity to emerging agents in order to better understand the nuanced dynamics in the indication.<\/p>\n","protected":false},"template":"","class_list":["post-395867","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-chronic-pain","biopharma-product-special-topics-other","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395867","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395867\/revisions"}],"predecessor-version":[{"id":396212,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/395867\/revisions\/396212"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=395867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}